A Study of Light Treatment Effectiveness (LITE) to Treat Psoriasis

Overview

About this study

The purpose of this study is to compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband ultraviolet B phototherapy for the treatment of psoriasis.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Willing and able to provide informed consent (age 18+) or parental permission and assent (ages 12-17).
  • Age 12 or older.
  • Plaque or guttate psoriasis predominantly located on trunk and/or extremities, with a physician global assessment average of > 1.0, and considered a candidate for phototherapy.
  • Patient is deemed willing and able to comply with either in-office or in-home phototherapy:
    • In office: Able to travel about 3 times per week for 12 weeks from home, work and/or school during business hours of local site;
    • In home: Has space to accommodate home phototherapy unit and patient (or if 12-17, parent), willing and able to follow home phototherapy instructions.
  • New or established patient in the practice.

Exclusion Criteria:

  • Patients who are judged unable or unwilling to comply with either in office or in home phototherapy due to time, work, school, or other financial constraints.
  • Patients judged unable to follow home phototherapy protocol due to failure to demonstrate understanding of the following: 
    • How to operate the phototherapy device;
    • How to follow the dosing protocol;
    • Requirement to wear protective eyewear and genital protection equipment.
  • Patients with known history of lack of efficacy to phototherapy or treated with phototherapy 14 days prior to baseline visit.
  • Psoriasis predominantly located on scalp, body folds, genitals, palms and/or soles or with a physician global assessment average of ≤ 1.0.
  • Patients deemed unsafe to be treated with phototherapy: 
    • History of photosensitivity or autoimmune disease such as lupus or dermatomyositis which can be aggravated by ultraviolet radiation;
    • History of arsenic intake;
    • Unable to tolerate standing for required duration of treatment due to age or physical function;
    • History of melanoma or multiple non-melanoma skin cancers that in the opinion of the principal investigator contraindicates treatment with phototherapy.
  • Clinical site deems the participant is ineligible for reason other than eligibility or screening criteria.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Aaron Mangold, M.D.

Open for enrollment

Contact information:

Rachel Kendrick

(480)301-6767

Kendrick.Rachel@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available